中文
North Augusta, SC – (March 24, 2026) – AmbioPharm, a global leader in custom synthetic peptide API development and manufacturing, today announced a significant expansion of its North Augusta, South Carolina facility. The investment strengthens the company’s U.S manufacturing footprint and enhances its ability to support innovative partners developing the next generation of peptide therapeutics.
The company added that the expansion is being advanced in parallel with discussions around state, local, and federal support for life sciences manufacturing, which will help inform the project’s final investment structure.
The expansion adds 68,000 square feet of purpose-built space designed for full upstream commercial synthesis, flexible SPPS, LPPS and hybrid synthesis, and large-scale, complex peptide programs. The site is engineered to meet the needs of late-stage and commercial projects.
The expansion is driven by the patients behind every peptide program.
“We have spoken with our client-partners about their growth, their challenges, and the pressures they face to move promising therapies forward without delay,” said Brian Gregg, CEO of AmbioPharm. “This expansion is our commitment to them and to the patients behind every program. We are investing ahead of demand, so our client-partners never have to slow down.”
The expanded North Augusta site strengthens AmbioPharm’s ability to deliver:
- Shorter lead times
- Fast, smoother tech transfer
- Dual-site flexibility
- Advanced technology that ensures consistent quality and scalability
“We have heard clearly that our client-partners need more than capacity, they need capability,” Gregg added. “They need a U.S. site that can take on complex, commercial-scale peptide projects. That’s what we are building.”
The investment positions AmbioPharm to support the rapidly expanding pipeline of peptide-based therapies. “As peptide therapies evolve, so must the infrastructure that supports them. This expansion ensures we can scale with our client-partners’ ambitions while maintaining the quality and reliability patients deserve,” said Gregg.
For additional insight into AmbioPharm’s expansion strategy and the evolving peptide manufacturing landscape, CEO Brian Gregg recently discussed the company’s expansion plans in a podcast interview with PharmaSource.
About AmbioPharm
AmbioPharm is a global custom synthetic peptide CDMO founded in 2005 and headquartered in North Augusta, South Carolina, USA specializing in developing highly efficient manufacturing processes for peptide-based Active Pharmaceutical Ingredients (APIs) at clinical and commercial stages. In our manufacturing facilities in South Carolina, USA and Shanghai, China, we manufacture New Chemical Entities (NCEs) under cGMP for clients worldwide. Both facilities have been inspected multiple times by the FDA as well as other global regulatory bodies with excellent outcomes. Our mission is to accelerate your peptides to patients.